Cadherin 17: A Target Opportunity To Develop Effector-Enhanced Drug Modalities - ResearchAndMarkets.com
Retrieved on:
Friday, August 5, 2022
The "Cadherin 17: A Target Opportunity To Develop Effector-Enhanced Drug Modalities" report has been added to ResearchAndMarkets.com's offering.
Key Points:
- The "Cadherin 17: A Target Opportunity To Develop Effector-Enhanced Drug Modalities" report has been added to ResearchAndMarkets.com's offering.
- There are more than 100 types of cadherins in humans, and many of them are not only responsible for cell adhesion but also involved in tumorigenesis.
- CDH17 provides a great opportunity for drug discovery and development as the competitive landscape still is very favorable for new entrants, but the first molecules have entered clinical development.
- The scientific rationale for CDH17-targeted therapies based on target characteristics and its differential expression profile;
Preclinical proof-of-concept of CDH17-targeted different drug modalities;
Clinical indications suitable for development of CDH17-targeted therapies and their patient populations;
The competitive landscape of CDH17-targeted drug modalities in development;
Specific profiles of CDH17-targeted drug modalities; and
Profiles of companies active in the development of anti-CDH17 therapy candidates.